Affiliations: [a] Southern Medical University, Guangzhou, Guangdong, China | [b] Department of Medical Oncology, Inner Mongolia Autonomous Region People's Hospital, Hohhot, China | [c] Department of Heart Center, Inner Mongolia Autonomous Region People's Hospital, Hohhot, China | [d] Department of Pathology, Inner Mongolia Autonomous Region People's Hospital, Hohhot, China | [e] Department of Radiation Oncology, Army General Hospital of PLA, Beijing, China
Correspondence:
[*]
Corresponding authpr: Yadi Wang, Department of Radiation Oncology, Army General Hospital of PLA, 100700, Beijing, China. Tel.: +86 10 66721629; E-mail:yadiwangpla@163.com
Abstract: BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is one of the
most common cause of cancer-associated mortality. Uncovering novel molecular
biomarkers that can predict ESCC development will improve personalized therapy. OBJECTIVE: The goal of the current study was to investigate the
expression pattern of miR-483-5p and determine its prognostic value in ESCC. METHODS: We first analyzed miRNA-seq data obtained from the Cancer
Genome Atlas (TCGA) cohort to evaluate the prognostic value of miR-483-5p in
ESCC. Then quantitative real-time RT-PCR (qRT-PCR) was carried out to
compare the miR-483-5p levels in 80 pairs of ESCC tissues and adjacent
non-cancerous tissues. The correlation between miR-483-5p levels and
clinical features were determined. RESULTS: For the TCGA cohort, ESCC patients with higher miR-483-5p
had significantly shorter overall survival time. The examined ESCC cancer
tissues exhibited a remarkable increment in miR-483-5p expression compared
with the adjacent normal tissues. miR-483-5p was positively correlated with
TNM stage, lymph nodes metastasis and T stage. In addition,
upregulate miR-483-5p expression was also found to be significantly
associated with poor survival of ESCC patients. Furthermore, miR-483-5p
expression was an independent prognostic factor for overall survival and
disease free survival in ESCC patients. CONCLUSIONS: Our study demonstrates that miR-483-5p might be a
tumor promoter of ESCC, which provide a promising prognostic biomarker and
therapeutic target.
